![Douglas A. Hamilton](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Douglas A. Hamilton
Chief Executive Officer at
METASTAT, INC.
Profile
Mr. Douglas A. Hamilton is a Principal at New Biology Ventures LLC.
Previously, he was the Chief Financial Officer at Javelin Pharmaceuticals Inc., (Formerly Intrac Inc.) from March 1999 to May 1, 2006 and served as Chief Operating Officer from December 2004 to February 2006 and also served as Chief Accounting Officer and Treasurer.
He is a Founder at Intrac Inc. and served as its Secretary.
He was the Chief Operating Officer at IDDS (Innovative Drug Delivery Systems ...
Inc.) since April 2001 and Chief Financial Officer since March 1999.
Previously, he served as Chief Financial Officer and Project Manager of Trisenox(R) at PolaRx BioPharmaceuticals.
From March 1999 to August 2002, he also concurrently served as Director, Business Development at Paramount Capital Investments, LLC.
From October 1997 to March 1999, he served as Project Manager at Zithromax(R) and Vfend(R) in addition to being a member of the Strategic Asset Management (SAM) task force in Central Research at Pfizer, Inc. From August 1993 to October 1997.
Mr. Hamilton was a Project Manager at Amgen Inc. for EPOGEN(R), Aransep(R) and STEMGEN(R), among other products, and assumed responsibility for developing and leading a research and development portfolio management system.
He has also served in various capacities at other biopharmaceutical companies including sales and marketing at Pharmacia, business development at NPS Allelix Biopharmaceuticals, Inc. and research at Pasteur Merieux Connaught.
Mr. Hamilton holds a M.B.A. from the Richard Ivey School of Business and a B.S.
in Molecular Biology and Molecular Genetics from the Department of Medical Genetics at the University of Toronto.
Douglas A. Hamilton active positions
| Companies | Position | Start |
|---|---|---|
| METASTAT, INC. | Chief Executive Officer | 2015-06-16 |
Vasomune Therapeutics, Inc.
 Vasomune Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Develops medications for treatment of diseases associated with vascular dysfunction | Chief Executive Officer | 2018-10-08 |
Former positions of Douglas A. Hamilton
| Companies | Position | End |
|---|---|---|
S.E.A. Medical Systems, Inc.
 S.E.A. Medical Systems, Inc. Medical SpecialtiesHealth Technology Develops medical devices that catch serious or life-threatening intravenous drug errors | Director of Finance/CFO | 2013-12-31 |
Javelin Pharmaceuticals, Inc.
 Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical drugs | Director of Finance/CFO | 2006-05-11 |
Intrac, Inc.
 Intrac, Inc. Financial ConglomeratesFinance Development stage company | Director of Finance/CFO | 2005-09-08 |
PolaRx Biopharmaceuticals
 PolaRx Biopharmaceuticals Miscellaneous Commercial ServicesCommercial Services Manufactures TriOxide drugs for the treatment of leukemia and other cancers | Director of Finance/CFO | 2002-07-30 |
Paramount Capital Investments LLC | Corporate Officer/Principal | 1999-02-27 |
Training of Douglas A. Hamilton
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
78
1st degree connections
16
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 16 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Pfizer Inc.
 Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
Intrac, Inc.
Intrac, Inc. Financial ConglomeratesFinance Development stage company | Finance |
Innovative Drug Delivery Systems, Inc.
 Innovative Drug Delivery Systems, Inc. Pharmaceuticals: MajorHealth Technology Researches and develops pharmaceutical products | Health Technology |
S.E.A. Medical Systems, Inc.
S.E.A. Medical Systems, Inc. Medical SpecialtiesHealth Technology Develops medical devices that catch serious or life-threatening intravenous drug errors | Health Technology |
Allelix Biopharmaceuticals, Inc.
 Allelix Biopharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops protein therapeutics and neuropharmaceuticals | Health Technology |
PolaRx Biopharmaceuticals
PolaRx Biopharmaceuticals Miscellaneous Commercial ServicesCommercial Services Manufactures TriOxide drugs for the treatment of leukemia and other cancers | Commercial Services |
University of Toronto
 University of Toronto Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Javelin Pharmaceuticals, Inc.
Javelin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical drugs | Health Technology |
Pharmacia, Inc. | |
Pasteur Mérieux Connaught | |
Paramount Capital Investments LLC | |
New Biology Ventures LLC
 New Biology Ventures LLC Investment ManagersFinance New Biology Ventures invests in companies located in the united States. The firm target companies operating in the fields of development and commercialization of life science tools, medical devices and therapeutic biopharmaceuticals. It provides financing for seed and early stage capital requirements. | Finance |
MetaStat, Inc.
 MetaStat, Inc. Electrical ProductsProducer Manufacturing Develops cancer diagnostics technologies | Producer Manufacturing |
Vasomune Therapeutics, Inc.
Vasomune Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Develops medications for treatment of diseases associated with vascular dysfunction | Health Technology |
Western University
 Western University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
- Stock Market
- Insiders
- Douglas A. Hamilton
